CytoMed Therapeutics (CytoMed Therapeutics) Debt-to-EBITDA : -0.13 (As of Dec. 2023)

CytoMed Therapeutics Debt-to-EBITDA Chart

Competitive Comparison of CytoMed Therapeutics's Debt-to-EBITDA

For the Biotechnology subindustry, CytoMed Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CytoMed Therapeutics's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytoMed Therapeutics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where CytoMed Therapeutics's Debt-to-EBITDA falls into.

CytoMed Therapeutics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

CytoMed Therapeutics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

CytoMed Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.

CytoMed Therapeutics  (NAS:GDTC) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

CytoMed Therapeutics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of CytoMed Therapeutics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

CytoMed Therapeutics (CytoMed Therapeutics) Business Description